Aktis Oncology (NASDAQ:AKTS) Shares Gap Up – Still a Buy?

Aktis Oncology (NASDAQ:AKTS)’s stock price gapped up before the market opened on Friday . The stock had previously closed at $19.46, but opened at $21.36. Aktis Oncology shares last traded at $21.3650, with a volume of 90,538 shares trading hands.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. HC Wainwright raised their target price on Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. William Blair began coverage on Aktis Oncology in a research report on Wednesday, April 29th. They set an “outperform” rating for the company. Finally, Weiss Ratings downgraded shares of Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research report on Tuesday. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.50.

Aktis Oncology Price Performance

The business has a fifty day moving average price of $19.13.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings data on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The company had revenue of $1.87 million during the quarter. On average, analysts anticipate that Aktis Oncology will post -1.62 earnings per share for the current year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.